561, p < 0.0001) or BR (r = −0.905, p < 0.0001) in teriparatide group. The same trends in the correlation between cortical thickness and the other parameters were observed in placebo group. The correlation between percent change in cortical thickness and BR at the femoral neck was higher in the teriparatide group (r 2 = 0.82) than in the placebo group (r 2 = 0.54).

There was no significant correlation between the percent change in cortical thickness and that of cortical vBMD in either group. To visualize the relationships of multiple buy DMXAA parameters at the individual level, the percent change in cortical thickness at the femoral neck was plotted on the horizontal axis of each panel in Fig. 4 versus the percent changes in cortical CSA (Fig. 4a), perimeter (Fig. 4b), SM (Fig. 4c),

and BR (Fig. 4d), GDC-0068 clinical trial separately for the teriparatide (solid lines) and placebo (dashed lines) groups. Each panel of Fig. 4 is divided into four quadrants and the percentages of closed circles (teriparatide) and open circles (placebo) included in each quadrant are provided in the figure. The linear regression lines are basically the same between the teriparatide and placebo groups. Further, with respect to parameters with positive correlations (Fig. 4a, c), the distribution of individual data in the teriparatide group is significantly different from placebo (cortical CSA: p = 0.0111, SM: p = 0.0250); weighted distribution of closed circles (teriparatide) in the first quadrant is high, while the open circles (placebo) are highly distributed in the third quadrant. Similarly, in the case of parameters with negative correlations (Fig. 4b, d), the distribution of closed circles (teriparatide) in the fourth quadrant is high, while the open circles (placebo) are highly distributed in the second quadrant. The difference between teriparatide and placebo is significant for BR (p = 0.0274). These results suggest that changes in the placebo group with natural aging (i.e., age-related deteriorations in

proximal femur geometry and biomechanical properties) are reversed at least partially by once-weekly teriparatide treatment. Fig. 4 Weekly administration of teriparatide reverses age-related changes at 72 weeks in cortical geometry and biomechanical properties Abiraterone at the femoral neck. Relationships between percent changes in cortical thickness versus those in cortical cross-sectional area (CSA) (a), perimeter (b), SM (c), or BR (d) are shown. Solid circles and open circles correspond to percent changes of individuals in the teriparatide and placebo groups, respectively. Note that linear regression lines for teriparatide (solid lines) and placebo (dashed lines) showing the relationship between the percent change in cortical thickness and those in other parameters, are almost identical regardless of whether the correlation is positive (a and c) or negative (b and d).